TESARO (TSRO) Phase 3 Niraparib Results a 'Grand Slam' - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Tesaro (TSRO) Valuation Range Lifted to $122-$132 at Wells Fargo
June 29, 2016 9:48 AM EDTWells Fargo analyst Jim Birchenough raised his valuation range on Outperform-rated Tesaro (NASDAQ: TSRO) to $122-$132 from $88-495 following today's positive NOVA results.
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $37.21 yesterday.
... MoreCredit Suisse Sees $157B of FCF Through 2019 Available for M&A in Biotech/Pharma Sector
June 29, 2016 7:56 AM EDTAnalysts at Credit Suisse evaluated potential M&A in the biotech sector beyond Medivation (NASDAQ: MDVN), which in addition to a hostile bid from Sanofi (NYSE: SNY) has been looked at by multiple firms.
Analysts led by Vamil Divan said... More
TESARO (TSRO) Nearly Doubles as Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:47 AM EDTTESARO (NASDAQ: TSRO) is surging 88% in pre-open trade after the company announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary... More
TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint
June 29, 2016 7:02 AM EDTTESARO, Inc. (NASDAQ: TSRO) announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline BRCA mutation (gBRCAmut) carriers, among patients who are not germline BRCA mutation (non-gBRCAmut) carriers but who have homologous recombination deficient (HRD) tumors as determined by the Myriad myChoice® HRD test, and overall in patients who are not germline BRCA mutation carriers.
We are extremely grateful to the patients, caregivers, and investigators who participated in... More
